Importantly, while weight reduction remains a cornerstone of MASLD management, evidence suggests that GLP-1 analogs also exert direct effects on hepatocytes, contributing to the attenuation of steatosis independently of weight loss [12], which constitutes a significant advantage over bariatric surgery by offering additional benefits with fewer potential complications. The gene discussed is GLP1R; the disease is steatosis.